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Recently the importance of CXCL10 in the pathogenesis of non-segmental vitiligo 
(NSV) and autoimmune thyroid disorders (AITD) has been shown. No data are 
present about chemokines CXCL10 (Th1 prototype) and CCL2 (Th2 prototype) 
circulating levels in NSV patients with/without thyroiditis (AT).  
Serum CXCL10 and CCL2 have been measured in 50 consecutive NSV patients, in 40 
consecutive patients with NSV and AT (NSV+AT), in 50 sex- and age-matched 
controls without AT (control 1) and in 40 sex- and age-matched patients with AT 
without NSV (control 2).  
Serum CXCL10 levels were significantly higher in control 2, than in control 1 (P = 
0.001; ANOVA). NSV patients have serum CXCL10 levels significantly higher than 
control 1, or control 2 (P = 0.001). NSV+AT patients have serum CXCL10 levels 
higher than control 1, or 2 (P < 0.001), and than NSV (P = 0.01).  
In conclusion, we first demonstrate high serum CXCL10 in NSV patients, overall in 
presence of AT and hypothyroidism, suggesting the importance of a common Th1 
immune response in their immune-pathogenesis. To evaluate if serum CXCL10 might 
be used as a clinical marker of NSV and/or AT further studies are needed. 
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Take-home messages: 
• Vitiligo is a skin disease characterized by pale patchy areas of depigmentation on 
the face, wrists and hands, that are initially small, but often tend to grow and change 
in shape. Two type of vitiligo are known: 1- non-segmental vitiligo (NSV) that is 
usually symmetrical in the location of depigmentation; 2- segmental vitiligo (SV) that 
differs in appearance, and it is not associated with autoimmune diseases. 
• NSV is an autoimmune disease arising from an autoimmune response against 
melanocytes in the skin, and it is often associated with other autoimmune disorders.  
• The importance of the Th1 immune response in the development of vitiligo, and of 
(C-X-C Motif) Receptor 3 (CXCR3) receptor and its chemokine CXCL10, has been 
shown, suggesting these could be novel targets of future therapeutical approaches. 
• Our study first demonstrates high serum levels of CXCL10 in patients with NSV 
and NSV+AT with respect to control 1 (without NSV or AT) and control 2 (without 
NSV) with thyroiditis. Serum CXCL10 levels of NSV+AT patients with thyroiditis 
were significantly higher than that of control 1, of NSV patients without thyroiditis or 
control 2 with thyroiditis; while no significant difference was observed about CCL2 in 
the four groups.  
• This suggests a predominance of the Th1 immune response in these patients. 
• Future studies in larger casistics will be needed to evaluate the potential 
usefullness of serum CXCL10 determination as prognostic marker of NSV or 
thyroiditis, and in the follow-up of NSV patients treated with different therapies. 
1. Introduction 
Vitiligo is a skin disease characterized by pale patchy areas of depigmentation on the 
face, wrists and hands, that are initially small, but often tend to grow and change in 
shape [1]. Two type of vitiligo are known: 1- non-segmental vitiligo (NSV) that is 
usually symmetrical in the location of depigmentation; 2- segmental vitiligo (SV) that 
differs in appearance, and it is not associated with autoimmune diseases [2]. NSV is 
an autoimmune disease arising from an autoimmune response against melanocytes in 
the skin, and it is often associated with other autoimmune disorders. NSV is a 
component of the autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy 
(APECED) (Autoimmune polyendocrine syndrome type 1 - APS1) and Schmidt 
(APS2) multiple autoimmune syndromes, and it is associated with pernicious anemia 
and Addison’s disease [3], too. Thyroid autoimmune disorders [4] or the presence of 
thyroid-specific autoantibodies have been shown in 15-25% of NSV patients [5-7].  
Recently several studies have shown [8-10] the importance of the Th1 immune 
response in the development of vitiligo, and of (C-X-C Motif) Receptor 3 (CXCR3) 
receptor and its chemokine CXCL10, suggesting these could be novel targets of future 
therapeutical approaches. 
Furthermore, recent reports have shown that the serum and/or the tissue expressions 
of CXCL10 are increased in organ specific autoimmune diseases, such as, type 1 
diabetes (T1D), autoimmune thyroiditis, Graves’ disease (GD), or  Graves’ 
ophthalmopathy (GO), or systemic rheumatological disorders, like rheumatoid 
arthritis, systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and HCV-
related cryoglobulinemia [11]. 
Here we report our data about the prototype Th1 chemokine CXCL10 circulating 
levels in NSV patients with or without thyroiditis, in comparison with the prototype 





2.1.1. NSV patients 
We studied 50 NSV patients (Table 1), not previously treated with 
immunosuppressive treatments, such as corticosteroids, calcineurin inhibitors and 
phototherapy, in whom a thyroid screening [history, physical examination, thyroid-
stimulating hormone (TSH), free triiodothyronine (FT3), free thyroxine (FT4), anti-
thyroglobulin (AbTg) and anti-thyroid peroxidase (AbTPO) antibodies measurements, 
and ultrasonography] excluded the presence of associated thyroid autoimmune 
disorders (a well known cause of high serum CXCL10), and without other well-
known systemic disorders, such as immuno-rheumatic, neoplastic, and infectious 
diseases. Patients were diagnosed with NSV with body surface area (BSA) 
involvement of  > 5% [12].  
2.1.2. NSV patients with autoimmune thyroiditis (NSV+AT) 
Patients (n=40) with NSV at first presentation, consecutively referred to our 
Department were recruited into this group. Only NSV patients who were not 
previously treated with immunosuppressive treatments, such as corticosteroids, 
calcineurin inhibitors and phototherapy, and in whom a thyroid screening (history, 
physical examination, TSH, FT3, FT4, AbTg and AbTPO antibodies measurements, 
and ultrasonography) demonstrated the presence of associated thyroid autoimmune 
disorders were included in this group (Table 1). 
2.2. Controls  
Two control groups were included. 
2.2.1. Control 1 
The first control group (control 1) consisted of 50 subjects (Table 1), extracted from a 
random sample of the general population from the same geographic area, coupled by 
sex and age (that is a well known counfounding factor [13]) with NSV patients, in 
whom a complete thyroid work-up (history, physical examination, TSH, FT3, FT4, 
AbTg, AbTPO, and ultrasonography) was available, and excluded the presence of 
thyroid or autoimmune disorders, or any kind of immunomodulant therapy.  
2.2.2. Control 2 
The second control group (control 2) consisted of 40 subjects (Table 1), extracted 
from a random sample of the general population from the same geographic area [14], 
coupled by sex and age (that is a well known counfounding factor [13]) with 
NSV+AT patients, in whom a complete thyroid work-up (history, physical 
examination, TSH, FT3, FT4, AbTg, AbTPO, and ultrasonography) was available, 
and demonstrated the presence of thyroid autoimmune disorders, but excluded the 
presence of other autoimmune disorders and any kind of immunomodulant therapy.  
In all patients and controls, a blood sample was collected in the morning, after 
overnight fasting, and serum was kept frozen until CXCL10 and CCL2 measurement. 
All study subjects gave their informed consent to the study, which was approved by 
the local Ethical Committee.  
Thyroid ultrasonography [15] was performed both in patients as in controls as 
previously reported, and thyroid blood flow (TBF) by color-flow doppler (CFD) 
was studied in all patients [16].  
2.3. Laboratory evaluation  
Laboratory evaluation included measurement of serum levels of TSH (reference 
range 0.3-3.6 µIU/mL), FT3, FT4, AbTg and AbTPO titers. Circulating FT3 and 
FT4 were measured by commercial RIA kits (AMERLEX-MAB FT3/FT4 Kit; 
Amersham, UK). Serum TSH (DiaSorin, USA), AbTPO and AbTg (ICN 
Pharmaceuticals, USA) were evaluated by IRMA methods. For AbTg, AbTPO, 
positivity was set at >100 UI/ml and >100 IU/mL, respectively. Values are given 
as mean ± SD for normally distributed variables.  
2.4. Chemokines Assay  
Serum CXCL10 levels were assayed by a quantitative sandwich immunoassay 
using a commercially available kit (R&D Systems, Minneapolis, MN), with a 
sensitivity ranging from 0.40-4.45 pg/mL. The intra- and inter-assay coefficients of 
variation were 3.1% and 6.7%. Serum CCL2 levels were assayed by a quantitative 
sandwich immunoassay using a commercially available kit (R&D Systems, 
Minneapolis, MN), with a sensitivity of less than 5.0 pg/mL. The intra- and inter-
assay coefficients of variation were 4.5% and 5.6%. 
2.5. Data analysis  
Values are given as mean ± SD for normally distributed variables. Mean group 
values were compared by using one-way analysis of variance (ANOVA) for 
normally distributed variables, otherwise by the Mann-Whitney U test. Proportions 
were compared by the χ2 test. Post-hoc comparisons on normally distributed 
variables were carried out using the Bonferroni-Dunn test. Univariate analysis was 
performed by simple regression. 
 
3. Results  
NSV, NSV+AT and controls 1 and 2 were not significantly different (due to the 
matching procedure) in relation to the demographic characteristics (Table 1).  
As expected, NSV+AT patients, and controls with AT (control 2) showed 
significantly higher thyroid autoantibodies levels, as well as hypoechogenicity and 
hypervascularity of the thyroid gland, and subclinical hypothyroidism in comparison 
to control 1, and NSV patients without AT.  
Serum CXCL10 levels were significantly (Table 1; Fig. 1) higher in control 2, than in 
control 1 (P = 0.001; ANOVA). NSV patients have serum CXCL10 levels 
significantly higher than control 1, or control 2 (P = 0.001). NSV+AT patients have 
serum CXCL10 levels higher than control 1, or 2 (P < 0.001), and than NSV (P = 
0.01).  
In order to better define the role of increased serum chemokines in AT, CXCL10 was 
studied in relation to clinical features of AT (age; gender; thyroid volume < 6 mL; 
thyroid hypoechoic pattern, or hypervascularity; AbTg or AbTPO positivity; 
subclinical hypothyroidism) in NSV+AT patients and control 2. Serum CXCL10 
levels were significantly increased in patients NSV+AT with a thyroid hypoechoic 
pattern with respect to those without a hypoechoic pattern (483 ± 165 vs. 364 ± 111; 
P = 0.01; ANOVA) and hypothyroidism (445 ± 137 vs. 351 ± 103; P = 0.04; 
ANOVA), and in control 2 with a thyroid hypoechoic pattern with respect to those 
without a hypoechoic pattern (178 ± 145 vs. 109 ± 121; P = 0.02; ANOVA), and 
hypothyroidism (184 ± 129 vs. 112 ± 119; P = 0.03; ANOVA).  
By defining a high CXCL10 level as a value at least 2 SD above the mean value of the 
control group (> 196 pg/mL), 4% of control 1, 32% of control 2, 82% of NSV and 
93% of NSV+AT, had high CXCL10 (P = 0.001; χ2).  
Serum CCL2 levels were not significantly different (Table 1; Fig. 2) in control 1 and 
control 2, NSV patients with or without thyroiditis. In order to better define the role of 
serum chemokine CCL2, it was studied in relation to clinical features of AT (age; 
gender; thyroid volume < 6 mL; thyroid hypoechoic pattern, or hypervascularity; 
AbTg or AbTPO; subclinical hypothyroidism) in NSV+AT patients and control 2, but 
no significant association was found (data not shown).  




Our study first demonstrates high serum levels of CXCL10 in patients with NSV with 
respect to control 1 and control 2 with thyroiditis. Serum CXCL10 levels of NSV+AT 
patients with thyroiditis were significantly higher than control 1, or NSV patients 
without thyroiditis or control 2 with thyroiditis. No significant difference was 
observed about CCL2 in the four groups. 
The most important cytokine associated with the Th1 immune response, interferon 
(IFN)-γ [17], acts through chemokines, that are small glycoproteins active for 
different cell types. CXCL10 (also called IP-10) is a chemokine, induced by IFN-γ in 
various cell types, as neutrophils, lymphocytes, endothelial cells, thyrocytes and other 
cells [18,19]. CXCL10 binds to its specific receptor CXCR3 (expressed by immune 
cells and also endothelial cells, mesangial cells, thyrocytes and other epithelial cells), 
regulating immune responses by the recruitment and activation of T cells, monocytes, 
and NK cells. Tissue CXCR3 and CXCL10 expressions are increased in different 
autoimmune diseases, and are determinant in leukocyte homing into the inflamed 
tissues, being involved in tissue damage [19]. Elevated CXCL10 levels in peripheral 
liquids are a marker of host immune response, particularly of a T helper (Th)1 
orientated immune response. In inflamed tissues, Th1 lymphocytes are recruited 
enhancing IFN-γ and tumor necrosis factor (TNF)-α production, that in turn stimulate 
CXCL10 secretion from the above reported cells, in this way creating an amplification 
feedback loop [11]. 
It has been recently shown that both human vitiligo and a mouse model of vitiligo 
reflect a IFN-γ-specific Th1 immune response in the skin, involving the IFN-γ-
dependent chemokines (CXCL9, 10, and 11) [8]. A gene expression profile was 
conducted to evaluate the key cytokine pathways involved in vitiligo. Such gene 
expression profile in lesional skin patches from vitiligo patients, that contained a T 
cell infiltrate, demonstrated a significant loss of melanocyte-specific transcripts in 
lesional skin with respect to healthy controls, while chemokine expression showed a 
predominantly Th1-mediated signature (IFNG-specific). Th1 chemokines (CXCL9, 
CXCL10, CXCL11, and CCL5) were strongly induced in vitiligo, with respect to 
adhesion molecules (as ICAM1 and VCAM1). CXCL10 was high in serum from 
patients with vitiligo, while CXCL9 and CXCL11 were not significantly different 
compared to healthy controls. Melanocyte-specific CD8+ T cells expressed CXCR3, 
differently from healthy controls [8].   
A mouse model of vitiligo was also used [9]. Krt14-Kitl* mice have several epidermal 
melanocytes, as human skin. Krt14-Kitl* mice develop epidermal depigmentation on 
their foot pads, ears, and tails, upon transfer of premelanosome protein-specific CD8+ 
T cells (PMELs) and in vivo activation recombinant vaccinia virus expressing their 
cognate antigen (PMEL). Gene expression profile of lesional skin from this mice with 
vitiligo showed a gene chemokines exspression similar to human vitiligo, with a Th1-
specific response in the skin, and expression of the IFN-γ-dependent chemokines 
(CXCL9, CXCL10, and CCL5). CXCR3 is expressed by autoreactive T cells, as in 
humans with this disease [8]. In order to evaluate whether CXCR3 is required for the 
development of depigmentation, either wild-type (WT) or Cxcr3−/− PMEL T cells 
were transferred to induce vitiligo, and it was observed that Cxcr3−/− T cells were 
unable to induce depigmentation [8]. In this mouse model of vitiligo, Cxcl10−/− hosts 
developed minimal depigmentation, leading to hypothesize that vitiligo depends on 
this chemokine. CXCL10 is determinant in directing migration of T cells within the 
skin, and it was required for T cell function more than simple recruitment [8]. Upon 
treatment of mice with either CXCL9 or CXCL10 neutralizing antibodies, 
neutralization of CXCL10 significantly reduced depigmentation in this model, while 
neutralization of CXCL9 did not. Interestingly, CXCL10 neutralization in mice with 
established, widespread depigmentation reverses the disease, as shown by 
repigmentation. These results evidence a critical role for CXCL10 in both the 
progression and maintenance of vitiligo, supporting inhibiting CXCL10 as a targeted 
treatment strategy [8]. 
On the base of the results of the above mentioned study [8] it was evaluated the effect 
of inhibition of IFN-γ in vitiligo. STAT1 activation is required for IFN-γ signaling and 
recent studies revealed that simvastatin, an FDA-approved cholesterol-lowering 
medication, inhibited STAT1 activation in vitro. Therefore, it was hypothesized that 
simvastatin may be an effective treatment for vitiligo. In fact, simvastatin both 
prevented and reversed depigmentation in the mouse model of vitiligo, and reduced 
the number of infiltrating autoreactive CD8+ T cells in the skin. Treatment of 
melanocyte-specific, CD8+ T cells in vitro decreased proliferation and IFN-γ 
production, suggesting additional effects of simvastatin directly on T cells. Based on 
these data, it has been suggested that simvastatin may be a safe, targeted treatment 
option for patients with vitiligo [10].  
Interestingly, our data are in agreement with the results of another recent study 
reporting that serum CXCL9 and CXCL10 were significantly elevated in vitiligo 
patients and were higher in patients in progressive stages than those in stable stages, 
while CCL2 levels were not significantly different from controls [20].   
NSV+AT patients have significantly increased serum CXCL10 than NSV patients. 
These data suggest that in presence of thyroiditis the further increase of serum 
CXCL10 levels may be due to the thyroiditis itself, and suggest a predominance of the 
Th1 immune response in presence of thyroiditis in NSV patients. In GD it has been 
shown that removal of the thyroid itself by surgery [21] or by radiodione [22] reduces 
the CXCL10 serum levels suggesting that the intrathyroidal lymphocytes and/or 
thyrocytes [22] may be the source of CXCL10 [23].  
So it could be speculated that a superimposed Th1 response is active in the thyroid of 
patients with NSV+AT, explaining the higher levels of CXCL10 in NSV+AT with 
respect to NSV. These data agree to what found in autoimmune thyroid disorders 
(AITD) of patients with hepatitis C virus (HCV) infection or mixed cryoglobulinemia 
[24, 25].  
Our data are also in agreement with our results in patients with AT, confirming higher 
levels of CXCL10 in presence of hypothyroidism and thyroid hypoechogenicity, thus 
suggesting that also in these patients CXCL10 may be regarded as a marker of a more 
aggressive thyroiditis [4, 26]. 
Longitudinal studies evaluating serum CXCL10 in large casistics of NSV will be 
necessary to evaluate if serum CXCL10 measurement could represent an easily 
assayable marker for clinical management of these patients. 
The association of autoimmune disorders is known [27], though its pathogenetic base 
is still under investigation [28, 29]. A prevalent Th1 immune pattern is present in 
target organs of patients with chronic AT, or GO, or type 1 diabetes, at the beginning 
of these diseases, as shown also by animal models and by data available in humans 
[23,30,31]. For example, also in the initial and active phase of mixed 
cryoglobulinemia, a prevalent Th1 immune profile is shown, that switches to Th2 in 
the inactive phase [25,32]. This Th1 immune reactivity at the onset of mixed 
cryoglobulinemia and AT, under the influence of genetic and environmental 
conditions, might lead to the appearance of autoimmune phenomena in different 
organs in the same subject [4]. 
In conclusion, our study first demonstrates higher serum levels of CXCL10 in patients 
with NSV and NSV+AT than in controls. Serum CXCL10 levels in NSV+AT patients 
with thyroiditis are significantly higher than those of NSV patients without thyroiditis, 
suggesting a predominance of the Th1 immune response in these patients.   
Future studies in larger casistics will be needed to evaluate the potential usefullness of 
serum CXCL10 determination as prognostic marker of NSV or thyroiditis, and in the 
follow-up of NSV patients treated with different therapies. 
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Fig. 1 Serum CXCL10 levels were significantly higher in control 2 thyroiditis (AT), 
than in control 1 (Control; P < 0.01; ANOVA). NSV without thyroiditis have serum 
CXCL10 levels significantly higher than control 1, or control 2 (P < 0.001). NSV+AT 
patients with thyroiditis have serum CXCL10 levels higher than, control 1, control 2 
with thyroiditis (P < 0.001), and than NSV (P < 0.05).  
 
Fig. 2 Serum CCL2 levels were similar in control 1 (control) and control 2 (AT), 
NSV, and  NSV+AT patients (P > 0.05).  
 
 Table 1. Thyroid status of control subjects (control 1), control with autoimmune 
thyroiditis (control 2), non-segmental vitiligo patients without (NSV) or with 
autoimmune thyroiditis (NSV+AT).  
 
 control 1 control 2 NSV NSV+AT p 
  thyroiditis without thyroiditis 
with 
thyroiditis  
n 50 40 50 40  
      
Age (years) 52 ± 11 57 ± 12 54 ± 12 57 ± 13 ns 
      
Gender (M/F) 18/32 13/27 18/32 13/27 ns 
      
Thyroid volume (mL) 11 ± 10 12 ± 11 13± 11 11± 10 ns 
      
Hypoechoic (%) 0 76 0 69 0.0001 
      
Hypervascular (%) 0 36 0 41 0.0001 
      
Serum TSH (µIU/mL) 1.1 ± 0.8 1.7 ± 1.7 1.2 ± 0.9 3.3 ± 3.1* 0.01 
      
AbTPO (IU/mL) 15 ± 12 231 ± 373° 15 ± 14 189 ± 432° 0.0001 
      
AbTg (IU/mL) 9 ± 12 145 ± 314° 13 ± 9 314 ± 423° 0.0001 
      
Subclin. hypothyroidim (%) 0 11 0 14 0.01 
      
CXCL10 (pg/mL) 90 ± 53 152 ± 128§ 221 ± 137§^ 329 ± 147§* 0.0001 
      
CCL2 (pg/mL) 386 ± 179 378 ± 152 360 ± 161 432 ± 360 ns 
      
Antithyroperoxidase antibody = AbTPO     
Antithyroglobulin antibody = AbTg      
Thyroid-stimulating hormone = TSH     
Antithyrotropin-receptor antibody = TRAb     
* P < 0.05 or less vs. control 1 or vs. autoimmune thyroiditis control 2, or vs. NSV. 
§ P < 0.05 or less vs. control 1 
^ P < 0.05 or less vs. control 1 or vs. autoimmune thyroiditis control 2. 
° P < 0.05 or less vs. control 1 and vs. NSV 
 
 
